

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM735502

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Mallinckrodt LLC		06/16/2022	Limited Liability Company: DELAWARE
SpecGX LLC		06/16/2022	Limited Liability Company: DELAWARE
Infacare Pharmaceutical Corporation		06/16/2022	Corporation: DELAWARE
Mallinckrodt Brand Pharmaceuticals LLC		06/16/2022	Limited Liability Company: DELAWARE
Ocera Therapeutics, Inc.		06/16/2022	Corporation: DELAWARE
Stratatech Corporation		06/16/2022	Corporation: DELAWARE
Mallinckrodt ARD IP Unlimited Company		06/16/2022	Private Unlimited Company: IRELAND
Mallinckrodt Hospital Products IP Unlimited Company		06/16/2022	Private Unlimited Company: IRELAND
Mallinckrodt Pharma IP Trading Unlimited Company		06/16/2022	Private Unlimited Company: IRELAND
RECEIVING PARTY DATA			
Name:	Wilmington Savings Fund Society, FSB, as Second Lien Collateral Agent		
Street Address:	500 Delaware Ave, 11th Floor		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	19801		
Entity Type:	Bank: UNITED STATES		
PROPERTY NUMBERS Total: 50			
Property Type	Number	Word Mark	
Registration Number:	3093264	ACTHAR	
Registration Number:	2255322	ACTHAR GEL	
Registration Number:	3507492	ANAFRANIL	
Registration Number:	4026448	CELLEX	
Registration Number:	4674634		
Registration Number:	4570773		
Registration Number:	4841528		

OP \$1265.00 3093264

Property Type	Number	Word Mark
Registration Number:	4536015	
Registration Number:	4674635	
Registration Number:	4706982	
Registration Number:	4003732	DSIR
Registration Number:	5406796	EXALGO
Registration Number:	4536715	FLEXTRANET
Registration Number:	2672085	FLOWMOR
Registration Number:	2234829	FLOWMOR
Registration Number:	5695589	H.P. ACTHAR GEL
Registration Number:	2109970	INOCAL
Registration Number:	4389669	INOCAL CADDY
Registration Number:	2185947	INOMAX
Registration Number:	4003735	INOMAX DSIR
Registration Number:	4389579	INOMAX TOTAL CARE
Registration Number:	3893703	INOPULSE
Registration Number:	2678500	INOTHERAPY
Registration Number:	2100392	INOVENT
Registration Number:	5129069	
Registration Number:	2332279	M
Registration Number:	1410012	MALLINCKRODT
Registration Number:	5036705	M MALLINCKRODT
Registration Number:	4641807	M MALLINCKRODT
Registration Number:	958455	METHADOSE
Registration Number:	4410417	NICU-PET
Registration Number:	3312981	NIKS
Registration Number:	5438448	OCERA
Registration Number:	636736	PARZONE
Registration Number:	1038108	RESTORIL
Registration Number:	2686302	ROXICODONE
Registration Number:	6088591	S
Registration Number:	6078032	S
Registration Number:	6078031	S SONORANT THERAPEUTICS
Registration Number:	6078030	S SONORANT THERAPEUTICS
Registration Number:	6056868	SONORANT
Registration Number:	2851513	STANATE
Registration Number:	3395813	STRATAGRAFT
Registration Number:	3342834	STRATATECH
Registration Number:	4115195	THERAKOS

Property Type	Number	Word Mark
Registration Number:	5406873	TOFRANIL
Registration Number:	4006506	UVADEX
Registration Number:	4074104	UVADEX
Registration Number:	3949903	UVAR XTS
Registration Number:	4940208	

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-494-5225

Email: ipteam@cogencyglobal.com

Correspondent Name: Stewart Walsh

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: COGENCY GLOBAL Inc.

Address Line 4: Washington, D.C. 20036

ATTORNEY DOCKET NUMBER: 1711949 TM IPSA

NAME OF SUBMITTER: Jordana Dreyfuss

SIGNATURE: /Jordana Dreyfuss/

DATE SIGNED: 06/17/2022

Total Attachments: 10

source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page3.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page4.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page5.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page6.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page7.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page8.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page9.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page10.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page11.tif
source=MNK - New 2L Notes - Notice of Grant of Security Interest in Trademarks [For Filing]#page12.tif

Notice of Grant of Security Interest in Intellectual Property

NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS, dated as of June 16, 2022 (this “Agreement”), made by the Pledgors signatory hereto (each, a “*Pledgor*”), in favor of Wilmington Savings Fund Society, FSB, as Second Lien Collateral Agent (as defined below).

Reference is made to the Second Lien U.S. Collateral Agreement, dated as of June 16, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the “*Second Lien U.S. Collateral Agreement*”), among Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124 boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (*R.C.S Luxembourg*) under number B 172.865 (the “*Issuer*”), Mallinckrodt CB LLC, a Delaware limited liability company (the “*US Co-Issuer*”, and together with the Issuer, the “*Issuers*”), each Guarantor listed on the signature pages thereof and each other Guarantor that becomes a party thereto after the Issue Date (together with the Issuer and the US Co-Issuer, collectively, the “*Pledgors*”), the New Second Lien Notes Trustee (as defined therein), the Takeback Second Lien Notes Trustee (as defined therein) and Wilmington Savings Fund Society, FSB, as collateral agent (together with its successors and assigns in such capacity, the “*Second Lien Collateral Agent*”) for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. *Terms*. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Second Lien U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the Second Lien U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. *Grant of Security Interest*. As security for the payment and performance, as applicable, in full of its Secured Obligations, each Pledgor pursuant to the Second Lien U.S. Collateral Agreement did, and hereby does, assign and pledge to the Second Lien Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “*IP Collateral*”):

all Trademarks of the United States of America, including those listed on Schedule I;

provided, however, that the foregoing pledge, assignment and grant of security interest will not cover any Excluded Property, including, without limitation, any “intent-to-use” trademark applications, to the extent that the grant of a security interest therein would impair the validity or enforceability of, or render void or voidable or result in the cancellation of the applicable grantor’s right, title or interest therein or in any trademark issued as a result of such application under applicable federal law.

SECTION 3. *Second Lien U.S. Collateral Agreement.* The security interests granted to the Second Lien Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Second Lien Collateral Agent pursuant to the Second Lien U.S. Collateral Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Second Lien Collateral Agent with respect to the IP Collateral are more fully set forth in the Second Lien U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Second Lien U.S. Collateral Agreement, the terms of the Second Lien U.S. Collateral Agreement shall govern.

SECTION 4. *Counterparts.* This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed signature page of this Agreement by facsimile transmission or other electronic transmission (i.e., a “pdf” or “tif” or other electronic transmission pursuant to procedures approved by the Second Lien Collateral Agent) shall be effective as delivery of a manually executed counterpart hereof and the words “execution,” “execute,” “signed,” “signature,” and words of like import in or related to this Agreement shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Pledgors and the Second Lien Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.


SECTION 5. *Governing Law.* **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

SECTION 6 Notwithstanding anything herein to the contrary, the lien and security interest granted to the Second Lien Collateral Agent pursuant to this Agreement and the exercise of any right or remedy by the Second Lien Collateral Agent hereunder are subject to the provisions of the First Priority/Second Priority Intercreditor Agreement. In the event of any conflict between the terms of the First Priority/Second Priority Intercreditor Agreement and this Agreement, the terms of the First Priority/Second Priority Intercreditor Agreement shall govern and control


[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MALLINCKRODT LLC
SPECGX LLC

By: 
Name: Stephen A. Welch
Title: President

INFACARE PHARMACEUTICAL CORPORATION
MALLINCKRODT BRAND PHARMACEUTICALS LLC
OCERA THERAPEUTICS, INC.
STRATATECH CORPORATION

By: 
Name: Stephen A. Welch
Title: Assistant Secretary

MALLINCKRODT ARD IP UNLIMITED COMPANY
MALLINCKRODT HOSPITAL PRODUCTS IP
UNLIMITED COMPANY
MALLINCKRODT PHARMA IP TRADING
UNLIMITED COMPANY

By: _____
Name: Bryan M. Reasons
Title: Director

MALLINCKRODT PHARMACEUTICALS IRELAND
LIMITED

By: _____
Name: Mark Casey
Title: Director

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.


MALLINCKRODT LLC
SPECGX LLC

By: _____
Name: Stephen A. Welch
Title: Chief Transformation Officer and
Treasurer

INFACARE PHARMACEUTICAL CORPORATION
MALLINCKRODT BRAND PHARMACEUTICALS LLC
OCERA THERAPEUTICS, INC.
STRATATECH CORPORATION

By: _____
Name: Stephen A. Welch
Title: Assistant Secretary

MALLINCKRODT ARD IP UNLIMITED COMPANY
MALLINCKRODT HOSPITAL PRODUCTS IP
UNLIMITED COMPANY
MALLINCKRODT PHARMA IP TRADING
UNLIMITED COMPANY

By:  _____
Name: Bryan M. Reasons
Title: Director

MALLINCKRODT PHARMACEUTICALS IRELAND
LIMITED

By: _____
Name: Mark Casey
Title: Director

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MALLINCKRODT LLC
SPECGX LLC

By: _____
Name: Stephen A. Welch
Title: Chief Transformation Officer and
Treasurer


INFACARE PHARMACEUTICAL CORPORATION
MALLINCKRODT BRAND PHARMACEUTICALS LLC
OCERA THERAPEUTICS, INC.
STRATATECH CORPORATION

By: _____
Name: Stephen A. Welch
Title: Assistant Secretary

MALLINCKRODT ARD IP UNLIMITED COMPANY
MALLINCKRODT HOSPITAL PRODUCTS IP
UNLIMITED COMPANY
MALLINCKRODT PHARMA IP TRADING
UNLIMITED COMPANY

By: _____
Name: Bryan M. Reasons
Title: Director

MALLINCKRODT PHARMACEUTICALS IRELAND
LIMITED

By:  _____
Name: Mark Casey
Title: Director

WILMINGTON SAVINGS FUND SOCIETY, FSB,
as Second Lien Collateral Agent

By: John McNichol
Name: John McNichol
Title: Assistant Vice President

Schedule I
to Notice of Grant of Security Interest in Trademarks

U.S. Trademark Registrations and Applications

Country	Trademark	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
United States of America	ACTHAR	78/649502	13-Jun-05	3093264	16-May-06	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	ACTHAR GEL	75/445831	6-Mar-98	2255322	22-Jun-99	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	ANAFRANIL	77/305293	16-Oct-07	3507492	30-Sep-08	Registered	SpecGx LLC
United States of America	CELLEX	77489274	3-Jun-08	4026448	13-Sep-11	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	COLOR TEAL - HORIZONTAL STRIP	86/283,394	16-May-14	4674634	20-Jan-15	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	COLOR TEAL - CURVED STRIP	85/915,748	26-Apr-13	4570773	22-Jul-14	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	COLOR TEAL - CURVED STRIP (updated)	86/637344	21-May-15	4841528	27-Oct-15	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	COLOR TEAL - TOP OF TANK AND BOTTOM WAVY STRIP	85/915,731	26-Apr-13	4536015	27-May-14	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	COLOR TEAL - TOP OF TANK AND TOP & BOTTOM WAVY STRIP	86/283,412	16-May-14	4674635	20-Jan-15	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	COLOR TEAL - TOP PROTECTOR/HANDLE	86/283,424	16-May-14	4706982	24-Mar-15	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	DSIR	85070932	24-Jun-10	4003732	26-Jul-11	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	EXALGO	87/542359	25-Jul-17	5406796	20-Feb-18	Registered	SpecGx LLC

Country	Trademark	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
United States of America	FLEXTRANET	86/062,864	12-Sep-13	4536715	27-May-14	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	FLOWMOR	76386540	21-Mar-02	2672085	7-Jan-03	Registered	SpecGx LLC
United States of America	FLOWMOR (STYLIZED)	75/197784	13-Nov-96	2234829	23-Mar-99	Registered	SpecGx LLC
United States of America	H.P. ACTHAR GEL	88017262	27-Jun-18	5695589	12-Mar-19	Registered	Mallinckrodt ARD IP Unlinitied Company
United States of America	INOCAL	75/124,073	24-Jun-96	2109970	28-Oct-97	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOCAL CADDY	85791544	30-Nov-12	4389669	20-Aug-13	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOMAX	75/342495	18-Aug-97	2185947	1-Sep-98	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOMAX DSIR	85/071349	25-Jun-10	4003735	26-Jul-11	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOMAX TOTAL CARE	85/737439	25-Sep-12	4389579	20-Aug-13	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOPULSE	85031549	6-May-10	3893703	21-Dec-10	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOTHERAPY	75751044	24-Jun-99	2678500	21-Jan-03	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	INOVENT	75/124072	24-Jun-96	2100392	23-Sep-97	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	Lung Device	87082377	23-Jun-16	5129069	24-Jan-17	Registered	Mallinckrodt Hospital Products IP Unlinitied Company
United States of America	M in box - stylized	75/669100	26-Mar-99	2332279	21-Mar-00	Registered	Mallinckrodt LLC

Country	Trademark	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
United States of America	MALLINCKRODT	73525945	8-Mar-85	1410012	23-Sep-86	Registered	Mallinckrodt Brand Pharmaceuticals LLC
United States of America	MALLINCKRODT w/ Cube Logo Version 2	85646924	8-Jun-12	5036705	6-Sep-16	Registered	Mallinckrodt Brand Pharmaceuticals LLC
United States of America	MALLINCKRODT w/ Cube Logo Version 2 (in Color)	85845125	8-Feb-13	4641807	18-Nov-14	Registered	Mallinckrodt Brand Pharmaceuticals LLC
United States of America	METHADOSE	72409510	6-Dec-71	958455	8-May-73	Registered	SpecGx LLC
United States of America	NICU-PET	85836260	30-Jan-13	4410417	1-Oct-13	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	NIKS	75/928861	26-Feb-00	3312981	16-Oct-07	Registered	Stratatech Corporation
United States of America	OCERA	78968521	6-Sep-06	5438448	3-Apr-18	Registered	Ocera Therapeutics, Inc.
United States of America	PARZONE	72/002436	10-Feb-56	636736	6-Nov-56	Registered	SpecGx LLC
United States of America	RESTORIL	73/058683	25-Jul-75	1038108	20-Apr-76	Registered	SpecGx LLC
United States of America	ROXICODONE	76401917	24-Apr-02	2686302	11-Feb-03	Registered	SpecGx LLC
United States of America	S Logo (B&W)	88464907	7-Jun-19	6088591	30-Jun-20	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	S Logo (Color)	88464898	7-Jun-19	6078032	16-Jun-20	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	S Sonoran Therapeutics Logo (B & W)	88464893	7-Jun-19	6078031	16-Jun-20	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	S Sonoran Therapeutics Logo (Color)	88464881	7-Jun-19	6078030	16-Jun-20	Registered	Mallinckrodt Pharmaceuticals Ireland Limited

Country	Trademark	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
United States of America	Sonorant	88459416	4-Jun-19	6056868	19-May-20	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	STANATE	76/408361	15-May-02	2851513	8-Jun-04	Registered	Infacare Pharmaceutical Corporation
United States of America	STRATAGRAFT	78/540747	1-Jan-05	3395813	11-Mar-08	Registered	Stratatech Corporation
United States of America	STRATATECH	77/088429	22-Jan-07	3342834	27-Nov-07	Registered	Stratatech Corporation
United States of America	THERAKOS	77489277	3-Jun-08	4115195	20-Mar-12	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	TOFRANIL	87543724	26-Jul-17	5406873	20-Feb-18	Registered	SpecGx LLC
United States of America	UVADDEX	77489275	3-Jun-08	4006506	2-Aug-11	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	UVADDEX	85319332	12-May-11	4074104	20-Dec-11	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	UVAR XTS	77/948145	2-Mar-10	3949903	26-Apr-11	Registered	Mallinckrodt Pharmaceuticals Ireland Limited
United States of America	YIN-YANG DESIGN (black & white version)	86/694083	15-Jul-15	4940208	19-Apr-16	Registered	Mallinckrodt Pharmaceuticals Ireland Limited